NASDAQ:LJPC

La Jolla Pharmaceutical - LJPC Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: N/A
50-Day Range: $3.12
▼
$6.22
52-Week Range: N/A

Volume: 66,708 shs
Average Volume: 158,476 shs
Market Capitalization: $155.11 million

P/E Ratio: 51.84
Dividend Yield: N/A
Price Target: N/A

About La Jolla Pharmaceutical (NASDAQ:LJPC) Stock

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

Receive LJPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

LJPC Stock News Headlines

September 18, 2022 | americanbankingnews.com

La Jolla Pharmaceutical (NASDAQ:LJPC) Earns Buy Rating from Analysts at StockNews.com

September 2, 2022 | finance.yahoo.com

LJPC Dec 2022 5.000 call(CONTRA

August 11, 2022 | markets.businessinsider.com

Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan

July 28, 2022 | morningstar.com

La Jolla Pharmaceutical Co Stock News

July 16, 2022 | benzinga.com

Equity Alert - The M&A Class Action Firm Announces the Investigation of La Jolla Pharmaceutical Co. - LJPC

July 14, 2022 | apnews.com

LA JOLLA PHARMACEUTICAL COMPANY ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of LJPC and Encourages Investors to Contact the Firm

July 11, 2022 | finance.yahoo.com

How this Peninsula company is turning lung drug royalties into acquisitions

July 11, 2022 | markets.businessinsider.com

Dow Dips Around 90 Points; La Jolla Pharmaceutical Shares Surge

July 11, 2022 | marketwatch.com

La Jolla Shares Take Flight on Takeover by Innoviva >LJPC

July 11, 2022 | tmcnet.com

LJPC Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of La Jolla Pharmaceutical Company Is Fair to Shareholders

July 11, 2022 | benzinga.com

Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal

May 16, 2022 | finance.yahoo.com

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate Progress

April 28, 2022 | finance.yahoo.com

The past five years for La Jolla Pharmaceutical (NASDAQ:LJPC) investors has not been profitable

April 27, 2022 | stocknews.com

3 Biotech Stocks Under $5 to Buy Now

March 9, 2022 | finance.yahoo.com

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Corporate Progress

January 24, 2022 | finance.yahoo.com

What Kind Of Shareholders Own La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

January 13, 2022 | nasdaq.com

La Jolla Pharmaceutical Company Common Stock (DE) (LJPC)

November 17, 2021 | finance.yahoo.com

La Jolla Pharmaceutical Company Announces Share Repurchase Plan

November 8, 2021 | nasdaq.com

Shareholders in La Jolla Pharmaceutical (NASDAQ:LJPC) are in the red if they invested five years ago

November 4, 2021 | finance.yahoo.com

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Corporate Progress

November 4, 2021 | finance.yahoo.com

La Jolla Pharmaceutical (LJPC) Reports Q3 Loss, Tops Revenue Estimates

November 1, 2021 | finance.yahoo.com

La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

October 25, 2021 | finance.yahoo.com

La Jolla Pharmaceutical (NASDAQ:LJPC) shareholders have endured a 79% loss from investing in the stock five years ago

September 24, 2021 | marketwatch.com

Kidney Fibrosis Treatment Market Growth Predictions, Top Manufacturers, Regional Segmentation, Business Strategy and Demand Status by 2026

August 5, 2021 | finance.yahoo.com

La Jolla Pharmaceutical (LJPC) Tops Q2 Earnings and Revenue Estimates

See More Headlines

Receive LJPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

LJPC Company Calendar

Last Earnings: 5/16/2022
Today: 9/26/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LJPC
CUSIP: N/A
CIK: 920465
Web: www.lajollapharmaceutical.com
Phone: (617) 715-3600
Fax: 858-626-2851
Employees: 61
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.12
Trailing P/E Ratio: 51.84
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $19.66 million
Net Margins: 8.54%
Pretax Margin: 8.64%
Return on Equity: -5.46%
Return on Assets: 4.00%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.02
Quick Ratio: 3.52

Sales & Book Value

Annual Sales: $75.72 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 7.95
Book Value: ($2.94) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 24,937,000
Free Float: 15,885,000
Market Cap: $155.11 million
Optionable: Optionable
Beta: 2.39

Key Executives

Mr. Larry G. Edwards (Age 50)
Pres, CEO & Director
Comp: $858.87k

Mr. Michael S. Hearne (Age 59)
CFO & Sec.
Comp: $207.38k

Ms. Paula Rusu
VP of Operations

Ms. Sandra Vedrick
Sr. Director of Investor Relations & HR

Mr. Luke Seikkula (Age 58)
Sr. VP of Pharmaceutical Operations

Dr. Lakhmir S. Chawla M.D. (Age 51)
Consultant

Mr. Stewart M. Kroll (Age 63)
Chief Devel. Officer

Mr. Mark D. Williams
Sr. VP of Medical Affairs

Mr. Tony N. Hodges FACP
M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LJPC Stock - Frequently Asked Questions

When is La Jolla Pharmaceutical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our LJPC earnings forecast.
How were La Jolla Pharmaceutical's earnings last quarter?: La Jolla Pharmaceutical (NASDAQ:LJPC) posted its quarterly earnings data on Monday, May, 16th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by $0.16. The biopharmaceutical company earned $10.43 million during the quarter, compared to the consensus estimate of $13.10 million. La Jolla Pharmaceutical had a net margin of 8.54% and a negative trailing twelve-month return on equity of 5.46%.
What is George F. Tidmarsh's approval rating as La Jolla Pharmaceutical's CEO?: 8 employees have rated La Jolla Pharmaceutical Chief Executive Officer George F. Tidmarsh on Glassdoor.com. George F. Tidmarsh has an approval rating of 49% among the company's employees. This puts George F. Tidmarsh in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of La Jolla Pharmaceutical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), Intercept Pharmaceuticals (ICPT), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Advanced Micro Devices (AMD), El Pollo Loco (LOCO), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), NVIDIA (NVDA) and XOMA (XOMA).
What is La Jolla Pharmaceutical's stock symbol?: La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."
Who are La Jolla Pharmaceutical's major shareholders?: La Jolla Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include HealthInvest Partners AB (4.95%), Millennium Management LLC (0.41%), Hollencrest Capital Management (0.31%), Renaissance Technologies LLC (0.23%), O Shaughnessy Asset Management LLC (0.20%) and OLD National Bancorp IN (0.16%). Insiders that own company stock include Darryl Wellinghoff, David A Ramsay and Kevin C Tang.
View institutional ownership trends.
How much money does La Jolla Pharmaceutical make?: La Jolla Pharmaceutical (NASDAQ:LJPC) has a market capitalization of $0.00 and generates $75.72 million in revenue each year. The biopharmaceutical company earns $19.66 million in net income (profit) each year or $0.12 on an earnings per share basis.
How can I contact La Jolla Pharmaceutical?: La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The official website for the company is www.lajollapharmaceutical.com. The biopharmaceutical company can be reached via phone at (617) 715-3600, via email at info@ljpc.com, or via fax at 858-626-2851.

This page (NASDAQ:LJPC) was last updated on 9/26/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial Subscription Here

La Jolla Pharmaceutical - LJPC Stock Forecast, Price & News

About La Jolla Pharmaceutical (NASDAQ:LJPC) Stock

LJPC Stock News Headlines

LJPC Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

LJPC Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources